title: The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84).
abstract: BACKGROUND
  Factors contributing to PTH resistance in dialysis patients remain elusive.
  
  
  OBJECTIVE
  The study assessed the skeletal and biochemical response to 46 h of PTH(1-34) infusion in dialysis patients.
  
  
  METHODS
  The study was a prospective, controlled assessment of response to PTH(1-34).
  
  
  METHODS
  The study was performed at the University of California, Los Angeles, General Clinical Research Center.
  
  
  METHODS
  Nineteen dialysis patients and 17 healthy volunteers were studied.
  
  
  METHODS
  PTH(1-34) was infused at a rate of 8 pmol/kg x h for 46 h. Bone biopsy was performed in all dialysis patients.
  
  
  METHODS
  Serum calcium, phosphorus, 1,25-dihydroxyvitamin D, PTH (four separate assays), and FGF-23 were determined at baseline and h 7, 23, 35, and 46 of the infusion.
  
  
  RESULTS
  Serum calcium levels rose in healthy volunteers (9.2 +/- 0.1 to 11.9 +/- 0.3 mg/dl; P < 0.01) and in dialysis patients with adynamic/normal bone turnover (9.0 +/- 0.3 to 10.7 +/- 0.7 mg/dl; P < 0.05) but did not change in dialysis patients with high bone turnover. Serum phosphorus levels declined in healthy volunteers (3.9 +/- 0.1 to 3.5 +/- 0.1 mg/dl; P < 0.05) but increased in all dialysis patients (6.7 +/- 0.4 to 8.0 +/- 0.3 mg/dl; P < 0.05). Full-length PTH(1-84) declined in all subjects; however, PTH(7-84) fragments declined only in healthy subjects and in dialysis patients with normal/adynamic bone but remained unchanged in dialysis patients with high bone turnover.
  
  
  CONCLUSIONS
  The skeleton of dialysis patients with high bone turnover is resistant to the calcemic actions of PTH. PTH(7-84) may contribute to this phenomenon.
authors.affiliation: David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California 90095, USA. kwesseling@mednet.ucla.edu
authors.forename: Katherine
authors.initials: K
authors.lastname: Wesseling-Perry
authors.forename: G Chris
authors.initials: GC
authors.lastname: Harkins
authors.forename: He-jing
authors.initials: HJ
authors.lastname: Wang
authors.forename: Robert
authors.initials: R
authors.lastname: Elashoff
authors.forename: Barbara
authors.initials: B
authors.lastname: Gales
authors.forename: Mara J
authors.initials: MJ
authors.lastname: Horwitz
authors.forename: Andrew F
authors.initials: AF
authors.lastname: Stewart
authors.forename: Harald
authors.initials: H
authors.lastname: Jüppner
authors.forename: Isidro B
authors.initials: IB
authors.lastname: Salusky
mesh_terms: D000293:Adolescent; D001846:Bone Development / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D002113:Calcification, Physiologic / Q000187:drug effects; D002118:Calcium / Q000097:blood* / Q000652:urine; D005260:Female; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000097:blood; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D010281:Parathyroid Hormone / Q000502:physiology / Q000627:therapeutic use*; D010446:Peptide Fragments / Q000502:physiology*; D010758:Phosphorus / Q000097:blood; D006435:Renal Dialysis; D055815:Young Adult
chemical_list: C000717427:FGF23 protein, human; D010281:Parathyroid Hormone; D010446:Peptide Fragments; C414937:parathyroid hormone (7-84); D010758:Phosphorus; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23; D002118:Calcium
references.citation: J Clin Endocrinol Metab. 2006 Aug;91(8):3144-9
references.pmid: 16735491
references.citation: Kidney Int Suppl. 1990 Sep;29:S28-35
references.pmid: 2170736
references.citation: J Clin Endocrinol Metab. 2009 Feb;94(2):511-7
references.pmid: 19050056
references.citation: Kidney Int. 2003 May;63(5):1801-8
references.pmid: 12675856
references.citation: Am J Pathol. 2006 Dec;169(6):2161-70
references.pmid: 17148678
references.citation: Kidney Int. 1998 Sep;54(3):907-14
references.pmid: 9734615
references.citation: J Bone Miner Res. 1995 Sep;10(9):1393-9
references.pmid: 7502712
references.citation: Kidney Int. 2005 Mar;67(3):1171-8
references.pmid: 15698459
references.citation: Kidney Int. 2000 Aug;58(2):753-61
references.pmid: 10916099
references.citation: J Clin Endocrinol Metab. 2009 Jan;94(1):17-20
references.pmid: 18854401
references.citation: Endocrinology. 2001 Apr;142(4):1386-92
references.pmid: 11250917
references.citation: Ann N Y Acad Sci. 2007 Nov;1116:485-93
references.pmid: 17646263
references.citation: Nat Genet. 2006 Nov;38(11):1248-50
references.pmid: 17033625
references.citation: Pediatr Nephrol. 2009 Jul;24(7):1355-61
references.pmid: 19301038
references.citation: J Endocrinol. 2007 Oct;195(1):125-31
references.pmid: 17911404
references.citation: J Biol Chem. 2003 Oct 31;278(44):43787-96
references.pmid: 12920119
references.citation: Clin Exp Nephrol. 2007 Mar;11(1):34-40
references.pmid: 17384996
references.citation: Nephrol Dial Transplant. 1996 Oct;11(10):2008-16
references.pmid: 8918715
references.citation: Kidney Int. 2006 Feb;69(3):531-7
references.pmid: 16395276
references.citation: Am J Kidney Dis. 2003 Oct;42(4 Suppl 3):S1-201
references.pmid: 14520607
references.citation: J Clin Invest. 2007 Dec;117(12):4003-8
references.pmid: 17992255
references.citation: Nephrol Dial Transplant. 2005 Sep;20(9):1904-11
references.pmid: 15985520
references.citation: J Clin Invest. 2003 Sep;112(5):683-92
references.pmid: 12952917
references.citation: Ann Intern Med. 1973 Mar;78(3):357-64
references.pmid: 4571863
references.citation: Am J Physiol Renal Physiol. 2008 Oct;295(4):F1126-33
references.pmid: 18701629
references.citation: J Bone Miner Res. 2005 Oct;20(10):1792-803
references.pmid: 16160737
references.citation: Endocrinology. 1989 Sep;125(3):1617-22
references.pmid: 2759035
references.citation: Kidney Int. 1994 Sep;46(3):855-61
references.pmid: 7996807
references.citation: J Clin Invest. 2004 Feb;113(4):561-8
references.pmid: 14966565
references.citation: J Clin Endocrinol Metab. 1992 Jul;75(1):145-50
references.pmid: 1619003
references.citation: J Bone Miner Res. 1987 Dec;2(6):595-610
references.pmid: 3455637
references.citation: J Clin Endocrinol Metab. 2003 Apr;88(4):1603-9
references.pmid: 12679445
references.citation: J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):381-8
references.pmid: 17293108
references.citation: Kidney Int. 1995 Jun;47(6):1797-805
references.pmid: 7643551
references.citation: Kidney Int. 2005 Sep;68(3):998-1007
references.pmid: 16105030
references.citation: Endocrinology. 2002 Jan;143(1):171-6
references.pmid: 11751606
references.citation: Matrix Biol. 2004 Nov;23(7):421-32
references.pmid: 15579309
references.citation: Kidney Int. 2005 Sep;68(3):1236-43
references.pmid: 16105056
references.citation: Osteoporos Int. 2003 Sep;14 Suppl 5:S113-5; discussion S115-7
references.pmid: 14504715
references.citation: Clin Nephrol. 1999 Sep;52(3):160-6
references.pmid: 10499311
references.citation: Bone. 2005 Jun;36(6):971-7
references.pmid: 15869926
references.citation: Kidney Int. 1998 May;53(5):1358-64
references.pmid: 9573553
references.citation: Nephron Clin Pract. 2005;101(2):c94-9
references.pmid: 15956805
references.citation: Kidney Int. 2003 Dec;64(6):2272-9
references.pmid: 14633152
references.citation: Kidney Int. 2001 Oct;60(4):1460-8
references.pmid: 11576360
references.citation: Endocrinology. 2003 Apr;144(4):1135-8
references.pmid: 12639892
references.citation: Semin Nephrol. 1986 Mar;6(1):56-67
references.pmid: 3299577
references.citation: Kidney Int. 1998 Jan;53(1):205-11
references.pmid: 9453020
references.citation: J Bone Miner Res. 2004 Mar;19(3):429-35
references.pmid: 15040831
references.citation: Kidney Int. 2005 Mar;67(3):1120-5
references.pmid: 15698453
references.citation: J Clin Endocrinol Metab. 1999 Nov;84(11):4287-90
references.pmid: 10566687
references.citation: Eur J Endocrinol. 2006 Jan;154(1):93-9
references.pmid: 16381997